New hope in the fight against antibiotic resistant "super caps"

An unbreakable antibiotic-resistant hood has become a chilling outlook in the United States, which raises concerns that someone has ever had to live with sexually transmitted bacteria.

But now there is reason to hope. The newly developed antibiotic pill has proven to be effective against cavities in early clinical trials.

Zoliflodacin has proven to be effective in treating infections of the urinary and sexual tracts and the capillary rectum, scientists say.

"Gonorrhea has become resistant to all the antibiotics that have ever been used, so right now we are on the last class of antibiotics that can be used," said lead researcher Dr. Stephanie Taylor, an infectious disease specialist in New Orleans.

"It's very, very encouraging as a potential new antibiotic," said Taylor, medical director of the Louisiana State University-CrescentCare Sexual Health Center.

The results of the study are published on November 8th New England Journal of Medicine.

In recent years, there has been a drastic increase in the number of caries in the United States.

More than 555,600 cases were reported at the national level in 2017, an 18% increase over the previous year, Dr. Susan Blank, Assistant Commissioner of the Department of Health and Mental Hygiene, New York. And between 2013 and 2017, the gonorrhea quota increased by 67%.

"It's a rapidly growing infection in the United States," Blank said. "We see some sharp increases, it's seldom fatal, but it can really deeply affect the quality of life."

Currently, people with a drop of light are treated with ceftriaxone, the only antibiotic that is still effective against bacteria, Taylor said.

"We know the drip has an incredible ability to develop resistance to antibiotics," Blank said. "Where we are now, the untreated gut is a real possibility."

Untreated gonorrhea can cause sterility in humans, as well as inflammatory pelvic disease, ectopic pregnancy and destructive arthritis, said Blank. Children infected with infected mothers may be blinded.

"Gonorrhea also greatly facilitates the transfer of HIV infection among sexual partners," said Blank, who wrote editorial news reports on new experimental results.

It's hard to heal

In this clinical study with 141 participants, zoliflodacin appeared to be almost as effective as ceftriaxone.

Zoliflodacin cured 96% of genital and urinary tract infections and 100% of rectal infections compared to 100% of ceftriaxone.

The new antibiotic was infected with throat infections, with a higher dose of 3 grams excluding only 82% of infections compared with 100% of ceftriaxone.

"That's the way the neck hood responded," Taylor said. "It was always hard to heal."

The most common side effects were gastrointestinal complaints and no one required patients to leave a new drug, Taylor said. One limitation was that only 12 women participated in the experiment.

This was the second of the three clinical trials needed to approve zoliflodacin in the United States. The Phase 3 exam will begin next year, Taylor said. If these studies were going well, the US Food and Drug Administration would have data available to evaluate and approve the antibiotic by 2020. The Agency has already awarded the antibiotic the "fast track" label.

Although the development of zoliflodacin is encouraging, more antibiotics have to be developed to prevent the treatment of gout and other antibiotic-resistant bacteria, Taylor and Blank said.

"Even if this antibiotic is perfect, we know the gonorrhea will be exaggerated," Blank said. "We need things in the back pocket, we do not know how fast it will overcome it."

Physicians and public health officials must also continue efforts to detect and treat gout, said Blank. People who are sexually active must use condoms to prevent the transmission of gout, which spreads disproportionately between blacks, hispanics and native Americans, she noted.

"Controlling gonorrhea in the population requires a whole range of related activities," Blank said.

The clinical trial was partially funded by Zoliflodacin Entasis Therapeutics, a partner developed by AstraZeneca.

Credit Image:

Source link